Multicomponent Language Treatment for Primary Progressive Aphasia
Trial Summary
What is the purpose of this trial?
Primary progressive aphasia (PPA) is a progressive neurological disorder that causes a gradual decline in communication ability as a result of selective neurodegeneration of speech and language networks in the brain. PPA is a devastating condition affecting adults as young as in their 50's, depriving them of the ability to communicate and function in society. As a result of improved diagnostic precision, PPA is now identified with greater accuracy and frequency and, increasingly, patients and their families seek options for behavioral treatments to ameliorate the devastating effects on their communication, prolong speech language skills, and maximize quality of life. Speech-language treatment outcomes from our group and others are encouraging, confirming that behavioral intervention may lead to improvements in trained behaviors and, for some interventions, lasting and generalized benefit. Most speech-language interventions for individuals with PPA that have been explored in the literature are restitutive, or impairment-based in nature, and have not addressed the full range of severity and phenotypic variability in this population. The investigators will evaluate the utility of a novel, multicomponent intervention that incorporates elements of restitutive (e.g., word finding strategic training, script training), compensatory (e.g., multimodal communication, communication book), and care partner-focused treatment to meet the needs of individuals varying in clinical presentation and severity.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It might be best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the Multicomponent Language Treatment for Primary Progressive Aphasia?
Research shows that communication partner training and video script training can help people with primary progressive aphasia improve their communication skills. Studies found that these treatments can increase confidence, improve language use, and maintain communication abilities over time, even as the condition progresses.12345
Is Multicomponent Language Treatment for Primary Progressive Aphasia safe for humans?
How is the Multicomponent Language Treatment for Primary Progressive Aphasia different from other treatments?
The Multicomponent Language Treatment for Primary Progressive Aphasia is unique because it combines multiple approaches, including communication partner training, lexical retrieval training, and video-implemented script training, to address the complex language challenges in PPA. This comprehensive approach aims to improve communication by involving both the person with PPA and their communication partners, which is not typically the focus of other treatments.12389
Research Team
Maya L Henry, PhD
Principal Investigator
University of Texas - Austin
Eligibility Criteria
This trial is for adults diagnosed with Primary Progressive Aphasia (PPA) who can still score at least 10 on the Mini-Mental State Examination. They must have a partner to attend sessions with them. It's not suitable for those with major visual/hearing issues, other cognitive/behavioral/motor impairments, or additional neurological/psychiatric conditions affecting language skills.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a multicomponent intervention incorporating restitutive, compensatory, and care partner-focused treatments
Follow-up
Participants are monitored for changes in script production accuracy, spoken naming, and other communication measures
Treatment Details
Interventions
- Multicomponent Communication Partner Training (Multi-CPT)
- Multicomponent Lexical Retrieval Training (Multi-LRT)
- Multicomponent Video Implemented Script Training in Aphasia (Multi-VISTA)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Texas at Austin
Lead Sponsor